A new anticoagulant was recently approved for use to prevent stroke in patients with atrial fibrillation. The drug is Pradaxa (Dabigatran Etexilate). It is expected that a significantly sized population of patients may begin taking this drug as part of their stroke prevention care in the future. The problem with this drug is there is no reversal agent available as there is for other anticoagulants. This could be problematic during the hospital management of some patients, such as those with multitrauma.
It will be helpful if EMS and other healthcare providers recognize the drug name and know that it is an anticoagulant. If a patient is taking the drug, please let the receiving hospital staff know during your EMS reports to ED staff.
Additional information can be found at: